---
title: "Compass Pathways publishes investor presentation on COMP360 psilocybin program, FDA filing progress and launch plans"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294963906.md"
description: "Compass Pathways outlined plans for a rolling NDA filing for COMP360 psilocybin in treatment-resistant depression, targeting completion by Q4 2026. A U.S. launch is aimed for H1 2027, pending FDA clearance. Two Phase 3 trials met primary endpoints with significant results. The company highlighted durable responses and is preparing commercial rollout through certified sites and specialty pharmacies."
datetime: "2026-08-05T12:07:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294963906.md)
  - [en](https://longbridge.com/en/news/294963906.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294963906.md)
generator: "portal-rs"
---

# Compass Pathways publishes investor presentation on COMP360 psilocybin program, FDA filing progress and launch plans

-   Compass Pathways outlined plans to file a rolling NDA for COMP360 psilocybin in treatment-resistant depression, targeting completion in Q4 2026. \* U.S. launch targeted for H1 2027, contingent on FDA clearance; Breakthrough Therapy designation cited alongside a Priority Review Voucher in TRD. \* Two Phase 3 trials, COMP005 and COMP006, met the primary endpoint on MADRS change at Week 6 with P<0.001. \* Company highlighted durability through 26 weeks with infrequent dosing; additional dosing described as deepening response in some patients. \* Commercial rollout planning centers on certified treatment sites, REMS readiness, specialty pharmacy or buy-and-bill distribution, payer engagement. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Pathways plc published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [CMPS.US](https://longbridge.com/en/quote/CMPS.US.md)

## Related News & Research

- [Compass Pathways publishes investor deck on COMP360 psilocybin therapy for treatment-resistant depression approval path](https://longbridge.com/en/news/291930081.md)
- [Compass Pathways says Phase 3 COMP006 study shows COMP360 psilocybin maintains benefit through week 26 in TRD](https://longbridge.com/en/news/291916719.md)
- [09:40 ETODG by MCG Expert Joins Workers' Comp Experts for Panel Discussion on Claims Consistency at National Comp 2026](https://longbridge.com/en/news/297662064.md)
- [OLLI: Strong Q2 earnings growth driven by new stores and tariff refunds, despite comp sales decline](https://longbridge.com/en/news/297799059.md)
- [Pershing Square Inc. (NYSE:PS) Short Interest Down 55.7% in August](https://longbridge.com/en/news/297409324.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**